PEREGRINE PHARMACEUTICAL, INC. said that the National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) awarded three grants to investigators to support research of bavituximab in combination with other therapeutics for the treatment of glioblastoma, head and neck cancer, and hepatocellular carcinoma. Funding for the three investigator-initiated clinical studies will take place through a $2...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
